OSIP-486823 (OSIP 486823)
(Synonyms: OSIP 486823; OSIP486823; CP248) 目录号 : GC33163OSIP-486823 (OSIP 486823) 是一种新型微管干扰剂,对蛋白激酶 G (PKG) 和微管具有独特的生物学效应。
Cas No.:200803-37-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | The SW480 human colon adenocarcinoma and NIH3T3 mouse fibroblast cell lines are seeded in six-well plates at a density of 3×104 per well, grown for 36 to 48 hours, and then exposed to increasing concentrations of each compound (e.g., OSIP-486823; 1, 2 and 4 μM) for 48 hours. Cell numbers are determined using a Coulter counter and results are expressed as a percentage of the control culture. All assays are done in triplicate. Data are analyzed in Excel and the IC50s are determined graphically from cell survival curves[1]. |
References: [1]. Xiao D, et al. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol Cancer Ther. 2006 Jan;5(1):60-7. |
OSIP-486823 is a novel microtubule-interfering agent with distinct biological effects on both protein kinase G (PKG) and microtubules.
OSIP486823 inhibits growth and induce apoptosis in SW480 human colon cancer cells, with IC50 of 0.1 μM. OSIP-486823 (OSIP486823) causes depolymerization of microtubules in interphase cells, inhibit spindle formation in mitotic cells, and induce multinucleated cells. Exisulind and the potent synthetic derivative OSIP-486823 are members of a new class of drugs known as selective apoptotic antineoplastic drugs that target cyclic guanosine 3′,5′-monophosphate phosphodiesterases (cGMP-PDE). OSIP-486823 also disrupts microtubule polymerization, perturbs mitotic spindle function, and arrests cells in mitosis in human glioma cells[1].
[1]. Xiao D, et al. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol Cancer Ther. 2006 Jan;5(1):60-7.
Cas No. | 200803-37-8 | SDF | |
别名 | OSIP 486823; OSIP486823; CP248 | ||
Canonical SMILES | O=C(NCC1=CC=CC=C1)CC(C2=C/3C=CC(F)=C2)=C(C)C3=C\C4=CC(OC)=C(OC)C(OC)=C4 | ||
分子式 | C29H28FNO4 | 分子量 | 473.54 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1118 mL | 10.5588 mL | 21.1175 mL |
5 mM | 0.4224 mL | 2.1118 mL | 4.2235 mL |
10 mM | 0.2112 mL | 1.0559 mL | 2.1118 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。